Showing 1261-1270 of 1564 results for "".
- EyePoint Pharmaceuticals Reports Positive 30-Day Safety Results for All Cohorts From DAVIO Trial of EYP-1901 for Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-reports-positive-30-day-safety-results-for-all-cohorts-from-the-davio-trial-of-eyp-1901-for-wet-amd/2479344/EyePoint Pharmaceuticals announced positive safety results from its phase 1 clinical trial of EYP-1901, a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (AMD). All dose cohorts have reached at least 30-day post-dosing foll
- Early Study Shows J&J’s One-Dose COVID-19 Vaccine Triggered Antibodies in all Participantshttps://modernod.com/news/early-study-shows-jjs-one-dose-covid-19-vaccine-triggered-antibodies-in-all-participants/2478759/Detailed phase 1/2a study findings published in the NEJM on Wednesday showed that all volunteers given Johnson & Johnson’s single-dose coronavirus vaccine Ad26.COV2.S had detectable neutralizing antibodies by day 57. In September, the company reported a preview of the interim results in
- AGTC Announces Completion of Enrollment in All Adult Dose Groups of its Ongoing Phase 1/2 Clinical Trials in Patients with Achromatopsiahttps://modernod.com/news/agtc-announces-completion-of-enrollment-in-all-adult-dose-groups-of-its-ongoing-phase-1-2-clinical-trials-in-patients-with-achromatopsia/2477389/Applied Genetic Technologies Corporation (AGTC) announced that it has completed the planned enrollment in all dose groups for adult patients (age 18 years or older), including the two higher dose groups, of its phase 1/2 clinical programs with achromatopsia due to mutation in the
- IOLCon Designed to Map Out the Road for Reliable IOL Calculationhttps://modernod.com/news/iolcon-is-mapping-out-the-road-for-reliable-iol-calculation/2480474/Internet database IOLCon announced updates to its website,
- American Academy of Ophthalmology Urges Members to Immediately Stop Routine Surgical and In-Office Visitshttps://modernod.com/news/american-academy-of-ophthalmology-urges-members-to-immediately-stop-routine-surgical-and-in-office-visits/2477412/Due to the COVID-19 pandemic, the American Academy of Ophthalmology (AAO) stated that all ophthalmologists cease providing any treatment other than urgent or emergent care immediately. The statement posted on the AAO website reads: “We now live and practice in a critically di
- Prevent Blindness Says West Virginia State House Bill Would Imperil Children’s Visionhttps://modernod.com/news/prevent-blindness-says-west-virginia-state-house-bill-would-imperil-childrens-vision/2482738/Prevent Blindness published a letter on its website Tuesday calling on the West Virginia State House to reject
- NovaBay Pharmaceuticals Announces the Availability of KN95 Disposable Masks on Avenova.comhttps://modernod.com/news/novabay-pharmaceuticals-announces-the-availability-of-kn95-disposable-masks-on-avenova-com/2477457/NovaBay Pharmaceuticals announced the availability of KN95 disposable air filter masks on the company’s website
- Aldeyra Therapeutics Achieves Statistical Significance for All Endpoints in Phase 3 Trial of Reproxalap in Allergic Conjunctivitishttps://modernod.com/news/aldeyra-therapeutics-achieves-statistical-significance-for-primary-and-secondary-endpoints-in-phase-3-trial-of-reproxalap-in-allergic-conjunctivitis-1/2481676/Aldeyra Therapeutics announced positive topline results from the phase 3 INVIGORATE-2 clinical trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational new drug, in patients with allergic conjunctivitis. The clinical trial successfully achieved statistical significance for t
- Aldeyra Therapeutics Achieves Statistical Significance for All Endpoints in Phase 3 Trial of Reproxalap in Allergic Conjunctivitishttps://modernod.com/news/aldeyra-therapeutics-achieves-statistical-significance-for-primary-and-secondary-endpoints-in-phase-3-trial-of-reproxalap-in-allergic-conjunctivitis/2479122/Aldeyra Therapeutics announced positive topline results from the phase 3 INVIGORATE clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug in patients with allergic conjunctivitis. The clinical trial successfully achieved statistical significance for the primary endpo
- Biden Aims to Release All Available COVID-19 Vaccine Doses to Speed Up Distribution: Reporthttps://modernod.com/news/biden-aims-to-release-all-available-covid-19-vaccine-doses-to-speed-up-distribution-report/2478739/President-elect Joe Biden will seek to release nearly every available dose of the coronavirus vaccine when he takes office later this month, a move that signals a departure from the Trump administration and the FDA’s current stance of holding back half of the US vaccine supply in order to e